Therapy Directory

Docetaxel clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Docetaxel as a study intervention. Browse Docetaxel recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 8:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1320

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Triple-negative Breast Cancer
Interventions: Carboplatin, Docetaxel, Pembrolizumab, Pegfilgrastim; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 9
States / cities: Fairway, Kansas • Kansas City, Kansas • Overland Park, Kansas + 4 more

Conditions: Breast Cancer
Interventions: cyclophosphamide, docetaxel, doxorubicin; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 5,351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 146
States / cities: Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 123 more

Conditions: Prostate Cancer
Interventions: Apalutamide, Androgen deprivation, Salvage radiation therapy, Docetaxel; Drug · Radiation
Lead sponsor: Andrew J. Armstrong, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Omaha, Nebraska • New York, New York • Cary, North Carolina + 2 more

Conditions: Breast Cancer
Interventions: docetaxel, paclitaxel, pertuzumab, pertuzumab-placebo, trastuzumab [Herceptin], trastuzumab emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,095 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 62
States / cities: Little Rock, Arkansas • La Jolla, California • Montebello, California + 55 more

Conditions: Chemotherapy-induced Peripheral Neuropathy
Interventions: Not listed
Lead sponsor: Disarm Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 10
States / cities: DeBary, Florida • Baltimore, Maryland • Ann Arbor, Michigan + 6 more

Conditions: Non Small Cell Lung Cancer, Lung Cancer
Interventions: FLT3 Ligand (CDX-301), anti-CD40 antibody (CDX-1140), SBRT; Drug · Biological · Radiation
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Non-Small Cell Lung Carcinoma
Interventions: BGB324, Docetaxel; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: Dallas, Texas • Lubbock, Texas

Conditions: Breast Cancer
Interventions: cyclophosphamide, Docetaxel, epirubicin hydrochloride, fluorouracil, ixabepilone; Drug
Lead sponsor: UNICANCER; Other
Eligibility: 18 Years and older · Female only
Enrollment: 762 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 17
States / cities: Scottsdale, Arizona • Denver, Colorado • Jacksonville, Florida + 14 more

Conditions: Carcinoma, Squamous Cell of Head and Neck
Interventions: Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Non Small Cell Lung Cancer
Interventions: OSE2101, Docetaxel, Pemetrexed; Biological · Drug
Lead sponsor: OSE Immunotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 10
States / cities: Burbank, California • Washington D.C., District of Columbia • Boca Raton, Florida + 7 more

Conditions: Head and Neck Cancer
Interventions: Docetaxel, Cisplatin, Cetuximab, Carboplatin; Drug
Lead sponsor: Stanford University; Other
Eligibility: 16 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 2
States / cities: Davis, California • Stanford, California

Conditions: Prostate Cancer
Interventions: licorice root extract, docetaxel; Dietary Supplement · Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New Brunswick, New Jersey

About this Docetaxel clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Docetaxel as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Docetaxel.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Docetaxel clinical trials

Filter and sort this therapy

Live official records

Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer

Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes

A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)

FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy

Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.

Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer

Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

About this Docetaxel clinical trials directory page